Double-Digit Revenue Expansion: Pipeline Milestones Fuel Growth (REGN Q1 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Regeneron achieved double-digit revenue growth in the first quarter of 2026, demonstrating how strong commercial execution across core franchises can successfully fund next-generation pipeline development. The company reported strong performance from key growth products, updated gross margin guidance due to a temporary Limerick manufacturing halt, and celebrated a historic first gene therapy approval.
Core Growth Engines Drive Record First Quarter Revenues
Regeneron achieved double-digit growth in both revenues and earnings in the first quarter of 2026, driven by robust performance in its core franchises. Total revenues expanded 19% year-over-year to $3.6 billion, propelled by strong commercial execution. Diluted non-GAAP earnings per share grew to $9.47, reflecting strong operational delivery alongside active research funding.
A temporary bulk manufacturing interruption at the Limerick, Ireland facility reduced the GAAP gross margin to 76%. Despite this temporary halt, the company sustained a non-GAAP gross margin on net product sales of 86%. This high operational efficiency enabled Regeneron to generate $848 million of free cash flow during the quarter.
Anticipated Sanofi Repayment Promises Margin Step-Up in Second Half
CFO Christopher Fenimore announced a favorable change in the capital timeline: "We now expect the Sanofi development balance to be fully repaid by the end of the second quarter. As a result, we expect Sanofi collaboration revenue to step up to reflect our full share of collaboration profits starting in the third quarter." Due to actual and expected costs from the Limerick manufacturing interruption, the company updated its full-year gross margin guidance to a range of 77% to 78%.
Blockbuster Immunology and Oncology Franchises Gain Global Share
Immunology and oncology therapies drove the company's strong brand performance. Global net sales for the DUPIXENT segment expanded to $4.9 billion on a constant currency basis, supported by broad-based demand across multiple approved indications. In the oncology segment, global product sales of Libtayo grew 54% to $438 million, driven by continued uptake in advanced cutaneous squamous cell carcinoma.
In the U.S. retina segment, EYLEA HD net product sales rose 52% year-over-year to $468 million, which now contributes a major portion of the total net sales for the retina franchise. For rare diseases, Regeneron received FDA approval for Otarmeni, marking its first gene therapy approval to restore hearing in children born with genetic hearing loss. Chief Scientific Officer George Yancopoulos highlighted published data showing that nearly half of the treated children regained normal hearing levels within one year.
Clinical Pipeline Progress and Strategic Collaborations Expand Platform
During the Q&A session, management addressed critical pipeline and regulatory milestones. In response to Morgan Stanley's question on whether progression-free survival differentiation for the LAG-3 antibody fianlimab is sufficient to capture share, Chief Scientific Officer George Yancopoulos stated that the metastatic melanoma study is also designed to observe overall survival benefits. Additionally, CEO Leonard Schleifer responded to questions regarding the resubmission of the EYLEA HD prefilled syringe application at Catalent Indiana, stating that reinspections are complete and a regulatory decision is anticipated during the current quarter.